| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
56,296,000 |
| Market
Cap: |
221.24(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$2.07 - $5.88 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Sutro Biopharma is a clinical stage drug discovery, development and manufacturing company focused on deploying its proprietary integrated cell-free protein synthesis platform, XpressCF™, to create a variety of protein therapeutics initially for cancer and autoimmune disorders. Co.'s two product candidates are wholly owned: STRO-001, an antibody-drug conjugates (ADC) directed against CD74, for patients with multiple myeloma and non-Hodgkin lymphoma; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
12,185 |
39,226 |
39,226 |
| Total Sell Value |
$0 |
$60,925 |
$186,802 |
$186,802 |
| Total People Sold |
0 |
1 |
2 |
2 |
| Total Sell Transactions |
0 |
1 |
3 |
3 |
| End Date |
2024-02-15 |
2023-11-14 |
2023-05-16 |
2022-05-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Hallam Trevor |
Chief Scientific Officer |
• – – |
2020-08-26 |
4 |
AS |
$9.04 |
$8,818 |
D/D |
(975) |
16,790 |
|
184% |
|
| Freund John Gordon |
Director |
– • – |
2020-08-19 |
4 |
S |
$8.72 |
$4,360,000 |
I/I |
(500,000) |
1,460,053 |
|
-135% |
|
| Hallam Trevor |
Chief Science Officer |
• – – |
2020-07-27 |
4 |
AS |
$8.06 |
$7,858 |
D/D |
(975) |
17,765 |
|
164% |
|
| Hallam Trevor |
Chief Science Officer |
• – – |
2020-05-26 |
4 |
AS |
$10.00 |
$9,753 |
D/D |
(975) |
19,715 |
|
10% |
|
| Newell William J |
CEO |
• • – |
2020-05-14 |
4 |
B |
$7.75 |
$499,999 |
D/D |
64,516 |
166,627 |
2.81 |
17% |
|
| Molina Arturo Md |
Chief Medical Officer |
• – – |
2020-05-14 |
4 |
B |
$7.75 |
$49,995 |
D/D |
6,451 |
12,083 |
2.74 |
17% |
|
| Fitzpatrick Linda A |
Chief People & Comm. Officer |
• – – |
2020-05-14 |
4 |
B |
$7.75 |
$24,994 |
D/D |
3,225 |
9,007 |
2.74 |
17% |
|
| Hallam Trevor |
Chief Science Officer |
• – – |
2020-04-27 |
4 |
AS |
$9.41 |
$9,183 |
D/D |
(975) |
20,690 |
|
36% |
|
| Hallam Trevor |
Chief Science Officer |
• – – |
2020-03-26 |
4 |
AS |
$9.69 |
$9,453 |
D/D |
(975) |
21,665 |
|
-21% |
|
| Hallam Trevor |
Chief Science Officer |
• – – |
2020-02-26 |
4 |
AS |
$10.47 |
$10,207 |
D/D |
(975) |
22,640 |
|
-23% |
|
| Hallam Trevor |
Chief Science Officer |
• – – |
2020-01-27 |
4 |
AS |
$10.51 |
$10,250 |
D/D |
(975) |
23,615 |
|
-16% |
|
| Hallam Trevor |
Chief Science Officer |
• – – |
2019-12-26 |
4 |
AS |
$11.08 |
$10,802 |
D/D |
(975) |
24,590 |
|
- |
|
| Hallam Trevor |
Chief Science Officer |
• – – |
2019-10-28 |
4 |
AS |
$9.98 |
$9,726 |
D/D |
(975) |
26,540 |
|
- |
|
| Molina Arturo Md |
Chief Medical Officer |
• – – |
2019-09-26 |
4 |
D |
$9.74 |
$28,986 |
D/D |
(2,976) |
5,632 |
|
- |
|
| Molina Arturo Md |
Chief Medical Officer |
• – – |
2019-09-26 |
4 |
OE |
$0.00 |
$0 |
D/D |
8,608 |
8,608 |
|
- |
|
| Albini Edward C |
CFO and Secretary |
• – – |
2019-09-26 |
4 |
D |
$9.74 |
$24,155 |
D/D |
(2,480) |
6,382 |
|
- |
|
| Albini Edward C |
CFO and Secretary |
• – – |
2019-09-26 |
4 |
OE |
$0.00 |
$0 |
D/D |
7,174 |
8,862 |
|
- |
|
| Shabbir Anik |
Chief Technical Ops. Officer |
• – – |
2019-09-26 |
4 |
D |
$9.74 |
$28,986 |
D/D |
(2,976) |
5,632 |
|
- |
|
| Shabbir Anik |
Chief Technical Ops. Officer |
• – – |
2019-09-26 |
4 |
OE |
$0.00 |
$0 |
D/D |
8,608 |
8,608 |
|
- |
|
| Hallam Trevor |
Chief Science Officer |
• – – |
2019-09-26 |
4 |
D |
$9.74 |
$60,300 |
D/D |
(6,191) |
27,515 |
|
- |
|
| Hallam Trevor |
Chief Science Officer |
• – – |
2019-09-26 |
4 |
OE |
$0.00 |
$0 |
D/D |
17,906 |
29,896 |
|
- |
|
| Newell William J |
CEO |
• • – |
2019-09-26 |
4 |
D |
$9.74 |
$128,753 |
D/D |
(13,219) |
106,118 |
|
- |
|
| Newell William J |
CEO |
• • – |
2019-09-26 |
4 |
OE |
$0.00 |
$0 |
D/D |
25,252 |
119,337 |
|
- |
|
| Fitzpatrick Linda A |
Chief People & Comm. Officer |
• – – |
2019-09-26 |
4 |
D |
$9.74 |
$25,509 |
D/D |
(2,619) |
5,782 |
|
- |
|
| Fitzpatrick Linda A |
Chief People & Comm. Officer |
• – – |
2019-09-26 |
4 |
OE |
$0.00 |
$0 |
D/D |
7,575 |
8,401 |
|
- |
|
219 Records found
|
|
Page 8 of 9 |
|
|
0.41 (9.45%) 
